The pathophysiology of acute pancreatitis, specifically focusing on the role of hypertriglyceridemia. https://t.co/4X5vkoOyA4

Arrowhead is pleased to announce that the FDA has granted Breakthrough Therapy Designation in severe hypertriglyceridemia (sHTG). Learn more: https://t.co/KTjhoaWPwI

Hypertriglyceridemia management pearls @COREIMpodcast #MedEd

We are thrilled to share that we received U.S. FDA Breakthrough Therapy designation for our investigational treatment for severe hypertriglyceridemia (sHTG). More details here: https://t.co/uEtjdKgRNt

1/ 🚨New 5 Pearls 🚨 Severe Hypertriglyceridemia @NatTgAlliance How quickly can triglycerides rise?  At what threshold are patients at risk of pancreatitis? or cardiovascular adverse outcomes?

CORE TIMi 72a/b presented as #LBCT #AHA25 studying olezarsen in severe hypertriglyceridemia with primary endpoint percent change in TG ♥️ Global study 1063 patients ♥️placebo compared with two doses ♥️1/4 female 👎🏽 🎯62% placebo control ⤵️ in TG 🎯 significant ⤵️ in non HDL:

Combo triple agonist for FGF21 R/ Glucagon R/ GLP1 R lowers triglycerides by 69% v placebo among individuals with severe hypertriglyceridemia in a ph2 trial of N=79 #AHA25

Hypertriglyceridemia is managed through a combination of lifestyle modifications and medications, with the primary goal of reducing triglyceride (TG) levels to minimize the risk of complications such as pancreatitis and cardiovascular disease. Olezarsen: This is a newer,

5 breakthroughs in medicine this week 1. Olezarsen reduces triglycerides and prevents pancreatitis 1-2% of adults have very high triglyceride levels (severe hypertriglyceridemia) which can cause pancreatitis – but we have no therapies to lower the risk In two phase 3 trials,

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months and in the incidence of acute pancreatitis than

New study in the NEJM shows #olezarsen (ApoC-III antisense) cut triglycerides by up to ~70% and reduced acute pancreatitis in patients with severe hypertriglyceridemia (TG ≥500 mg/dL). This moves ApoC-III inhibition beyond rare FCS, pointing to a much wider role in severe

✅عينة دم “مليانة دهون” يعني lipemic serum + ألم بطن شديد + ارتفاع amylase -> تدل على تشخيص محتمل وهو Hypertriglyceridemia-induced acute pancreatitis (التهاب البنكرياس الحاد الناتج عن ارتفاع شديد في الدهون / ثلاثي-غليسريدات). الفكرة كالتالي: لما مستوى الدهون (خصوصًا الـ

This is awesome progress for preventative medicine 1% of the population has very high triglycerides ('severe hypertriglyceridemia') which can cause pancreatitis Olezarsen lowers triglycerides, and becomes the first drug proven to cut pancreatitis risk in this population:

When I was a medical student, I vividly recall taking care of very very sick patients with acute pancreatitis in the ICU. Remarkable to see how APOC3 inhibition (here, olezarsen) is now shown to be a highly effective therapy for severe hypertriglyceridemia, esp among those with

Episode 13 of #ConversationswithDrKohli is live! 🚨 @VietHeartPA and I break down CV risk in hypertriglyceridemia, and why fibrates don’t make the cut. Watch now for key clinical insights! Full Story: https://t.co/XFyJWlWiqV

Lina Al Shafi, 20, is suffering from debilitating chronic pancreatitis and upper gastrointestinal bleeding, caused by familial hypertriglyceridemia, a genetic condition that can also trigger cardiovascular problems. Her treatment does not exist in Gaza: she needs an injection

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk: @NEJM @AHAScience #AHA25 🥸 Among patients with severe hypertriglyceridemia, treatment with olezarsen led to a significantly greater reduction in the triglyceride level at 6 months! 😱Summary 👇👇👇

Ionis is at #AHA25! We are looking forward to connecting with healthcare providers to discuss the unmet need and risks associated with severe hypertriglyceridemia (sHTG). Visit our disease education booth #4325 to learn more.

Our Ions were busy at #AHA25 this past weekend, exchanging knowledge & advancing our scientific understanding of severe hypertriglyceridemia (sHTG). It was an inspiring & energizing weekend full of hope & progress. Thank you to all who joined us in New Orleans. See you next year!